Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rabe

Showing results (51-60 of 646) with videos related to

Pageof 65
Sort By:
Lancet (London, England)|May 18, 2017
Chronic obstructive pulmonary diseaseKlaus F Rabe, Henrik Watz
Current Drug Targets|June 10, 2008
Animal models for human asthma: the perspective of a clinicianNorbert Krug, Klaus F Rabe
Chest|May 7, 2014
Rebuttal from Drs Suissa and RabeSamy Suissa, Klaus F Rabe
The Journal of Allergy and Clinical Immunology|April 11, 2000
Immune mechanisms of smooth muscle hyperreactivity in asthmaD Schmidt, K F Rabe
The Journal of Allergy and Clinical Immunology|November 1, 1992
The protective effect of low-dose inhaled fenoterol against methacholine and exercise-induced bronchoconstriction in asthma: a dose-response studyH Magnussen, K F Rabe
The New England Journal of Medicine|November 16, 2017
Advanced Non-Small-Cell Lung CancerMartin Reck, Klaus F Rabe
The New England Journal of Medicine|August 31, 2017
Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung CancerMartin Reck, Klaus F Rabe
Der Nervenarzt|January 1, 1978
[Problems of symptomatic pyknoleptic and impulsive-petit mal epilepsy. A discussion of epilepsy classification (author's transl)]H U Lange, F Rabe
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 1, 1992
Low dose fenoterol aerosol protects against histamine-induced bronchoconstriction in mild asthmatics: a dose response studyH Magnussen, K F Rabe
Chest|May 7, 2014
Point: were industry-sponsored roflumilast trials appropriate? YesSamy Suissa, Klaus F Rabe
Pageof 65

Showing results (51-60 of 646) with videos related to

Sort By:
Pageof 65
Lancet (London, England)|May 18, 2017
Chronic obstructive pulmonary diseaseKlaus F Rabe, Henrik Watz
Current Drug Targets|June 10, 2008
Animal models for human asthma: the perspective of a clinicianNorbert Krug, Klaus F Rabe
Chest|May 7, 2014
Rebuttal from Drs Suissa and RabeSamy Suissa, Klaus F Rabe
The Journal of Allergy and Clinical Immunology|April 11, 2000
Immune mechanisms of smooth muscle hyperreactivity in asthmaD Schmidt, K F Rabe
The Journal of Allergy and Clinical Immunology|November 1, 1992
The protective effect of low-dose inhaled fenoterol against methacholine and exercise-induced bronchoconstriction in asthma: a dose-response studyH Magnussen, K F Rabe
The New England Journal of Medicine|November 16, 2017
Advanced Non-Small-Cell Lung CancerMartin Reck, Klaus F Rabe
The New England Journal of Medicine|August 31, 2017
Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung CancerMartin Reck, Klaus F Rabe
Der Nervenarzt|January 1, 1978
[Problems of symptomatic pyknoleptic and impulsive-petit mal epilepsy. A discussion of epilepsy classification (author's transl)]H U Lange, F Rabe
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 1, 1992
Low dose fenoterol aerosol protects against histamine-induced bronchoconstriction in mild asthmatics: a dose response studyH Magnussen, K F Rabe
Chest|May 7, 2014
Point: were industry-sponsored roflumilast trials appropriate? YesSamy Suissa, Klaus F Rabe
Pageof 65